 By the new Medical Device Regulation the use of certain phthalates which are carcinogenic mutagenic toxic to reproduction or have endocrine disrupting properties above 0.1 by weight is only allowed after a proper justification . The SCHEER provide Guidelines on the benefit risk assessment of the presence of such phthalates in certain medical devices .

@highlight The guidelines provide a framework to perform a BRA to justify the presence of CMR or ED phthalates in medical devices.
@highlight They also describe the evaluation of possible alternatives for these phthalates used in medical devices.
@highlight Manufacturers are encouraged to generate data that are needed for the BRA on potential alternatives to be used in medical devices.
